市場調査レポート
商品コード
1433050

医薬品・バイオテクノロジーにおける資産買収取引 (2016~2024年)

Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024

出版日: | 発行: Current Partnering | ページ情報: 英文 300+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.49円
医薬品・バイオテクノロジーにおける資産買収取引 (2016~2024年)
出版日: 2024年03月01日
発行: Current Partnering
ページ情報: 英文 300+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の医薬品・バイオテクノロジーにおける各種資産 (事業資産、製品資産、ロイヤリティ資産、技術資産) の買収取引の締結情況について分析し、全体的な取引件数・取引額の推移や予測 (2016~2024年)、近年の代表的取引の事例、主要企業による取引締結の動き、技術別・治療領域別の契約条件の傾向、といった情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 資産買収取引の動向

  • イントロダクション
  • 資産買収取引の定義
  • 資産買収取引の動向 (2016年以降)
    • 資産買収取引の動向:年別 (2016~2024年)
    • 資産買収取引の動向:開発段階別 (2016~2024年)
    • 資産買収取引の動向:産業分野別 (2016~2024年)
    • 資産買収取引の動向:治療領域別 (2016~2024年)
    • 資産買収取引の動向:技術の種類別 (2016~2024年)
    • 資産買収取引の動向:最も活発な企業の場合 (2016~2024年)
  • 資産買収の提携取引を締結する理由
    • 事業資産
    • 製品資産
    • ロイヤリティ資産
    • 技術資産
  • 資産買収取引の将来性

第3章 資産買収取引の構造:概要

  • イントロダクション
  • 資産買収契約の構造

第4章 資産買収の主要な取引

  • イントロダクション
  • 上位の資産買収取引 (金額ベース)

第5章 資産買収取引:最も活発な取引締結企業25社

  • イントロダクション
  • 資産買収取引:最も活発な取引締結企業25社

第6章 資産買収取引:契約の内訳

  • イントロダクション
  • 資産買収契約 (2016~2024年)
  • 取引内訳
  • 取引内訳:資産買収の取引締結、企業名別 (A~Z)
  • 取引内訳:資産買収の取引締結、治療領域別
  • 取引内訳:資産買収の取引締結、技術の種類別

Wildwood Venturesについて

目次
Product Code: CP2054

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

  • Business assets
  • Product assets
  • Royalty assets
  • Technology assets
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
  • This report contains a comprehensive listing of asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
  • The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
  • Chapter 3 provides an overview of the structure of asset purchase deals.
  • Chapter 4 provides a review of the leading asset purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
  • Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
  • Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
  • The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
  • The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2016.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse asset purchase deals
  • Benchmark analysis - identify market value of transactions
  • Financials - headline, upfront, milestone, royalty rates
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in asset purchase dealmaking in the biopharma industry
  • Overview of asset purchase deal structure
  • Directory of asset purchase deal records covering pharmaceutical and biotechnology
  • The leading asset purchase deals by value
  • Most active asset purchase dealmakers
  • The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

  • 2.1. Introduction
  • 2.2. Types of assets purchased
  • 2.3. Trends in asset purchase deals since 2016
    • 2.3.1. Asset purchase dealmaking by year, 2016-2024
    • 2.3.2. Asset purchase dealmaking by phase of development, 2016-2024
    • 2.3.3. Asset purchase dealmaking by industry sector, 2016-2024
    • 2.3.4. Asset purchase dealmaking by therapy area, 2016-2024
    • 2.3.5. Asset purchase dealmaking by technology type, 2016-2024
    • 2.3.6. Asset purchase dealmaking by most active company, 2016-2024
  • 2.4. Reasons for entering into asset purchase partnering deals
    • 2.4.1. Business assets
    • 2.4.2. Product assets
    • 2.4.3. Royalty assets
    • 2.4.4. Technology assets
  • 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

  • 3.1. Introduction
  • 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

  • 4.1. Introduction
  • 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

  • 5.1. Introduction
  • 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

  • 6.1. Introduction
  • 6.2. Asset purchase deals with contracts 2016-2024
  • Deal directory
  • Deal directory - Asset purchase dealmaking by companies A-Z
  • Deal directory - Asset purchase dealmaking by therapy area
  • Deal directory - Asset purchase dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of assets purchased
  • Figure 2: Trends in asset purchase deal announcements, 2016-2024
  • Figure 3: Asset purchase deals signed at each phase of development, 2016-2024
  • Figure 4: Asset purchase deals by industry sector, 2016-2024
  • Figure 5: Asset purchase deals by therapy area, 2016-2024
  • Figure 6: Asset purchase deals by technology type, 2016-2024
  • Figure 7: Top 25 most active asset purchase dealmakers, 2016-2024
  • Figure 8: Top asset purchase deals by value, 2016-2024
  • Figure 9: Most active asset purchase dealmakers, 2016-2024